Worsening Heart Failure with a Potassium of 5.6

Answer to his question first: no. He is hypoxemic, has an AKI, and is hyperkalemic. This is an admission.

The precipitant is iatrogenic and reversible. Naproxen causes sodium and water retention, blunts diuretic response, and reduces afferent renal blood flow. Stop it now and label it.

Next hour, in order:

1. Airway/oxygenation - oxygen to keep SpO2 above 90%; sit him up; reassess work of breathing. If he is tachypneic and tiring despite oxygen, that changes the disposition to a higher level of care, not a floor bed.
2. Potassium - K 5.6 with normal-appearing ECG is urgent but not emergent. Obtain a repeat to rule out hemolysis, put him on telemetry, low-potassium diet, stop the NSAID, and start a potassium binder (patiromer or sodium zirconium cyclosilicate) so that you can keep his disease-modifying therapy. Reserve calcium, insulin/dextrose, and albuterol for ECG changes or K at 6.5 or above.
3. Congestion - he is fluid overloaded with a rising creatinine; that is cardiorenal congestion, and the treatment is decongestion, not fluids. Give IV loop diuretic (at least his oral dose intravenously, often 1-2.5x the oral dose given the reduced gut perfusion), reassess urine output in 2-4 hours, and add a thiazide-type agent such as metolazone if the response is poor.

What to do with his heart failure drugs:

• Spironolactone: hold. K 5.6 plus an AKI plus a precipitant is the one situation where the MRA comes off. Reassess in 48-72 hours.
• Sacubitril/valsartan: this is the trap. The reflex is to stop it. Guidelines are explicit that hyperkalemia and modest renal function decline should prompt treatment of the potassium and a search for the cause rather than down-titration of RAAS inhibition, because withdrawing it costs survival. With K 5.6 and an acute kidney injury, a temporary reduction or brief interruption while you fix the precipitant is defensible - but the documented plan must be a scheduled re-titration, not a permanent discontinuation. Write that plan in the chart.
• Carvedilol: continue unless he becomes hypotensive or in shock; do not stop beta-blockade for congestion alone.

Yes - start it. Dapagliflozin or empagliflozin reduces heart failure hospitalization and cardiovascular death in HFrEF regardless of diabetes status, and eGFR 34 is above the thresholds at which these drugs are initiated (roughly 20-25 mL/min/1.73 m2 depending on the agent). The absence of diabetes is not a contraindication; it is the point.

Before starting

• Volume status: an SGLT2 inhibitor is a mild diuretic. If he is euvolemic on high-dose loop diuretic, anticipate the need to reduce the loop dose to avoid hypotension and pre-renal injury.
• Check for genital hygiene issues, recurrent UTIs, ketosis-prone states, and any history of diabetic ketoacidosis.
• Baseline renal function and potassium for comparison.

What to expect and what to tell him

• Creatinine may rise by a small amount (an expected eGFR dip of roughly 3-5 mL/min) in the first weeks. This is a hemodynamic effect and is not a reason to stop the drug - counsel him in advance so he does not stop it himself when he sees the lab printout.
• Genital mycotic infections: hygiene counseling, report itching or discharge.
• Sick-day rules are the highest-yield teaching: hold the drug during acute illness with vomiting or poor intake, before surgery, and during prolonged fasting, because of euglycemic ketoacidosis risk. He should tell any clinician he takes it.
• No routine glucose monitoring is needed if he remains non-diabetic.

Also address at this visit

• Devices: EF 28% with a QRS of 118 ms - CRT is not indicated (QRS under 130 ms and not LBBB). An ICD should be discussed once he has had at least 3 months of optimized therapy and his EF remains 35% or less with a reasonable life expectancy and functional status; document the reassessment plan rather than simply deferring.
• Spironolactone re-challenge with a potassium binder is worth a try once he is stable, since MRA therapy carries a mortality benefit he is currently missing.

Make the abstract concrete. 'Weigh yourself every morning, after urinating, before eating, same scale, and write it on the calendar.' Give him a numeric action threshold rather than 'call if you gain weight' - for example, call the same day for a gain of more than 2-3 lb in 24 hours or more than 5 lb in a week, or for new shortness of breath lying flat or needing an extra pillow.

Build a written 'stop and call' list with three categories:

• Volume: the weight thresholds above, new ankle swelling, needing extra pillows.
• Perfusion: dizziness on standing, lightheadedness, resting pulse under 50 or above 110.
• Drugs: muscle cramps, vomiting, or diarrhea - with the sick-day rule to hold the SGLT2 inhibitor and call before taking diuretics during a GI illness.

The NSAID conversation must be explicit and repeated. He should be told, in plain words, that anti-inflammatory pain pills like ibuprofen and naproxen are the reason he was in the hospital, that they are dangerous with his heart and kidneys, and that acetaminophen or a topical gel is his pain option. Give him a card listing medications to avoid. Ask his pharmacy to flag NSAIDs.

Make it stick. Use teach-back: ask him to tell you the weight threshold and what he will do if he hits it, in his own words. Identify the person who will actually help him weigh and call. Simplify the regimen where possible and align dosing with his daily routine.

System side: a follow-up visit within 7-14 days, a heart failure nurse phone check within 72 hours, a scale he can actually use, and labs (potassium, creatinine) 1-2 weeks after any change in diuretic, MRA, or ARNI dose. Send him home with the phone number of a human being, not a general switchboard.